Clinical Trials Directory

Trials / Completed

CompletedNCT02501876

Type 2 Diabetes Mellitus as Catalyst for Alzheimer's Disease

Type 2 Diabetes Mellitus as Accelerator for the Progression to Alzheimer's Disease in Patients With Mild Cognitive Impairment

Status
Completed
Phase
Study type
Observational
Enrollment
202 (actual)
Sponsor
Hospital Universitari Vall d'Hebron Research Institute · Academic / Other
Sex
All
Age
65 Years – 90 Years
Healthy volunteers
Not accepted

Summary

In recent years, it has been observed that the type 2 diabetic patients (DM-2) have an increased risk of developing dementia, both vascular and Alzheimer's disease (AD). The term mild cognitive impairment (MCI) describes a transition state between normal cognitive function and dementia. The annual rate of conversion to dementia in MCI patients is around 15% in the general population, regardless of the presence or absence of diabetes. At present it is not possible to identify which patients with MCI are most likely to progress to AD. On this basis, the main objective of this study is to evaluate whether the presence of diabetes and or the presence of its related genes favors the conversion of MCI to AD.

Detailed description

In recent years, it has been observed that the type 2 diabetic patients (DM-2) have an increased risk of developing dementia, both vascular and Alzheimer's disease (AD). The term mild cognitive impairment (MCI) describes a transition state between normal cognitive function and dementia. The annual rate of conversion to dementia in MCI patients is around 15% in the general population, ie regardless of the presence or absence of diabetes. At present it is not possible to identify which patients with MCI are most likely to progress to AD. On this basis, the main objective of this study is to evaluate whether the presence of diabetes favors the conversion of MCI to AD. We propose a case-control study comparing a group of 110 diabetic patients and a group of 110 non-diabetic patients with MCI matched by age, sex and cardiovascular risk factors. The main objective is the conversion to AD between the groups and if DM-2 is an independent risk factor. The secondary objective is to investigate whether genetic mechanisms related both to AD and DM-2 are associated with the increased risk of AD in diabetic patients. We will analyze 10 genes simultaneously associated with an increased risk of diabetes and / or its complications and AD.

Conditions

Interventions

TypeNameDescription
OTHERThere is a retrospectiv observational study. No interventionThere is a retrospectiv observational study. No intervention will be performed

Timeline

Start date
2015-05-01
Primary completion
2015-09-01
Completion
2016-05-01
First posted
2015-07-17
Last updated
2017-04-12

Locations

1 site across 1 country: Spain

Source: ClinicalTrials.gov record NCT02501876. Inclusion in this directory is not an endorsement.